- In August 2022, ARTHEx Biotech launched ENTRY, a platform designed to advance its drug pipeline, which includes treatments for myotonic dystrophy, cancer cachexia, and osteoarthritis, by enabling tissue-enriched delivery of antimiRs
- In June 2022, A research team led by Rutgers Cancer Institute of New Jersey secured a USD 25 million Cancer Grand Challenges grant to investigate cancer cachexia, a debilitating condition often seen in the later stages of cancer
- In April 2021, Helsinn, a Swiss pharmaceutical company, in partnership with Ono Pharmaceutical, launched Adlumiz Tablets in Japan to treat cancer cachexia associated with malignant non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer
- In April 2021, Actimed Therapeutics Ltd entered into a license agreement with Faraday Pharmaceuticals, Inc. for S-oxprenolol, and Faraday acquired global rights to develop and commercialize the drug for cancer cachexia, with Actimed eligible for royalties on future sales
- In February 2021, Researchers from Trinity announced a partnership with Artelo Biosciences to expand research and explore new treatment options for cancer cachexia
Frequently Asked Questions
The market is segmented based on Segmentation, By Therapeutics (Progestogens, Corticosteroids, Combination Therapies, and Others), Mechanism of Action (Appetite Stimulators, Weight Loss Stabilizers, and Others), Distribution Channel (Hospital Stores, Retail Pharmacy Stores, and Online Pharmacy) – Industry Trends and Forecast to 2032
.
The Global Cancer Cachexia Market size was valued at USD 2.53 USD Billion in 2024.
The Global Cancer Cachexia Market is projected to grow at a CAGR of 4.65% during the forecast period of 2025 to 2032.
The major players operating in the market include Æterna Zentaris Inc., Alder BioPharmaceuticals Inc., Aphios Corp, Eli Lilly and Co., GTx Inc., Helsinn Group, Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Co., XBiotech Inc., Marsala Biotech Inc., Inovio PharmaceuticalsInc., Astellas Pharma Inc., AstraZeneca PLC, Biotest AG, Boehringer Ingelheim GmbH, Boston Biomedical, InteRNA Technologies B.V., ISU ABXIS Co.Ltd., AVEO PharmaceuticalsInc., Jiangsu Kanion Pharmaceutical Co.Ltd. .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
